Valuation: Insmed Incorporated

Market Cap 25.06B 21.98B 20.36B 18.73B 35.43B 2,398B 36.12B 243B 95.16B 1,178B 94.1B 92.04B 4,068B P/E 2026 *
-44.3x
P/E 2027 * 207x
Enterprise Value 24.49B 21.48B 19.9B 18.31B 34.63B 2,344B 35.3B 237B 93.01B 1,151B 91.97B 89.96B 3,976B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 8.76x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-5.47%
1 week-2.02%
Current month+2.50%
1 month+12.14%
3 months-27.69%
6 months-33.25%
Current year-37.20%
1 week 108.02
Extreme 108.02
119.54
1 month 93.92
Extreme 93.92
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
07-08Fiscal year

Chief Executive Officer

32,097 0.0148%
07-05Fiscal year

Chief Technology Officer

36,906 0.0170%
06-24Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-2.50%-2.02%+7.26%+421.17% 25.06B
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-0.89%-3.88%-18.66%-17.55% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-3.89%+0.75%+22.74%+189.12% 14.2B
-0.60%+0.70%+66.69%+137.45% 12.37B
Average -1.60%-0.57%+50.38%+190.89% 25.39B
Weighted average by Cap. -1.69%-1.41%+48.58%+164.64%

Financials

2026 *2027 *
Net sales 1.69B 1.48B 1.37B 1.26B 2.39B 162B 2.43B 16.34B 6.41B 79.31B 6.34B 6.2B 274B 2.75B 2.41B 2.23B 2.05B 3.89B 263B 3.96B 26.61B 10.44B 129B 10.32B 10.1B 446B
Net income -571M -501M -464M -427M -807M -54.64B -823M -5.53B -2.17B -26.83B -2.14B -2.1B -92.66B 83.9M 73.59M 68.15M 62.71M 119M 8.03B 121M 812M 319M 3.94B 315M 308M 13.62B
Net Debt -566M -496M -459M -423M -800M -54.13B -815M -5.48B -2.15B -26.58B -2.12B -2.08B -91.79B -983M -862M -799M -735M -1.39B -94.1B -1.42B -9.52B -3.73B -46.21B -3.69B -3.61B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-13 US$109.14 -5.60% 2,824,026
26-07-10 US$115.61 -2.24% 2,931,618
26-07-09 US$118.26 +1.48% 3,167,091
26-07-08 US$116.53 +3.27% 2,835,056
26-07-07 US$112.84 +1.17% 1,674,721
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
115.61USD
Average target price
196.33USD
Spread / Average Target
+69.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock